• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Contact Us
  • Our Google News Channel
IRA vs 401k

IRA vs 401k

Retirement Options

  • Home
  • Roth IRA
  • Roth 401k
  • SEP IRA
  • Simple IRA
  • 401K
  • Finanace
You are here: Home / Finanace / Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More

Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More

January 31, 2021 by Retirement

Biotech stocks alternated between gains and losses in the week ended Jan. 29 before ending lower. Big pharma earnings season kick started, with Novartis AG(NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Eli Lilly And Co (NYSE: LLY) all in the mix.

Coronavirus vaccine and treatment news flow abounded in the week. J&J and Novavax, Inc. (NASDAQ: NVAX) released top-line results from their respective late-stage vaccine studies. Merck & Co., Inc. (NYSE: MRK), meanwhile, dropped out of the vaccine race.

Lilly and Vir Biotechnology Inc (NASDAQ: VIR) announced a study combining their COVID-19 antibody treatments.

Biogen Inc (NASDAQ: BIIB) reacted with a move to the upside after the Food and Drug Administration extended the review period of its Alzheimer’s drug, aducanumab, by three months.

Here are the key catalytic events for the unfolding week:

Conferences

Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference: Feb. 3-4

PDUFA Dates

The FDA is scheduled to announce its verdict on Adamas Pharmaceuticals Inc‘s (NASDAQ: ADMS) new drug application for Gocovri as a treatment option for “off episodes” in Parkinson’s disease patients receiving levodopa-based therapy. The decision is due Monday, Feb. 1.

The agency will also decide on Mallinckrodt PLC‘s (OTC: MNKKQ) biologics license application for StrataGraft, an engineered tissue designed to mimic natural human skin, with both inner dermis-like and outer epidermis-like layers. StrataGraft is being evaluated as a treatment option for deep partial-thickness thermal burns. The PDUFA goal date is Tuesday, Feb. 2.

Related Link: Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation

Clinical Readouts

Turning Point Therapeutics Inc (NASDAQ: TPTX) will present at the IASLC World Conference On Lung Cancer updated data from the TRIDENT-1 study of its lead candidate repotrectinib in TKI-naive patients with ROS1-positive advanced non-small cell lung cancer (Sunday, Jan. 31).

Vaxart Inc (NASDAQ: VXRT) is expected to release data from the Phase 1 study of its oral COVID-19 vaccine candidate.

Earnings

Monday

Omnicell, Inc. (NASDAQ: OMCL)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the market close)

View more earnings on IBB

Tuesday

Bio-Techne Corp (NASDAQ: TECH) (before the market open)
Catalent Inc (NYSE: CTLT) (before the market open)
Haemonetics Corporation (NYSE: HAE) (before the market open)
Pfizer Inc. (NYSE: PFE) (before the market open)
Amgen, Inc. (NASDAQ: AMGN) (after the market close)

Wednesday

AbbVie Inc (NYSE: ABBV) (before the market open)
Biogen (before the market open)
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (before the market open)
Boston Scientific Corporation (NYSE: BSX) (before the market open)
Cardiovascular Systems Inc (NASDAQ: CSII) (after the market close)

Thursday

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) (before the market open)
Baxter International Inc (NYSE: BAX) (before the market open)
Bristol-Myers Squibb Co (NYSE: BMY (before the market open)
Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (before the market open)
Quest Diagnostics Inc (NYSE: DGX) (before the market open)
Twist Bioscience Corp (NASDAQ: TWST) (after the market close)
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the market close)
Misonix Inc (NASDAQ: MSON) (after the market close)
Gilead Sciences, Inc. (NASDAQ: GILD) (after the market close)

Friday

Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open)
Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open)

IPOs

Blacksburg, Virginia-based Landos Biopharma, Inc. has filed for an initial public offering of 6.25-million shares priced between $15 and $17 each. This clinical-stage biopharma develops oral therapeutics for patients with autoimmune diseases. It is expected to list its shares on the Nasdaq under the ticker symbol LABP.

Danish AI-immunology platform company Evaxion Biotech A/S is offering 2.75 million ADSs in an IPO, with each ADS representing one ordinary share. The company estimates a price range of $10-$12 for the offering. The company has applied for listing its shares on the Nasdaq under the ticker symbol EVAX.

Sana Biotechnology, Inc. is developing in-vivo and ex-vivo cell engineering platforms for developing treatments for a wide range of diseases. The company proposes to offer 15 million shares in an IPO, with an estimated price range of $20-$23. The Seattle-based company has applied for listing its shares on the Nasdaq under the ticker symbol SANA.

IPO Quiet Period Expiries

Gracell Biotechnologies Inc (NASDAQ: GRCL)

Other Events

Johnson & Johnson could file for emergency use authorization approval in the U.S. in the coming week. The company said in a release announcing topline results from the Phase 3 study of its vaccine candidate that an EUA filing will be done in early February.

Related Link: Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Filed Under: Finanace

Primary Sidebar

E-mail Newsletter

More to See

Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s

November 23, 2024 By Roth

IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024

November 21, 2024 By Roth

Real Estate Syndication in Indianapolis: Unlocking Investment Potential

November 15, 2024 By Retirement

Maximizing Your 401k at 55 | Retirement Strategies for Growth

October 15, 2024 By Roth

401(k) savings

Retirement Savings Options: Navigating the Path to a Secure Future

August 15, 2024 By SEO Robot

Retirement Planning

August 13, 2024 By Roth

Infographic comparing IRA vs 401(k) retirement options.

IRA and 401(k): Compare Your Retirement Options

May 20, 2024 By SEO Robot

Tags

401(k) 401(k) advantages 401(k) insights 401k at 55 401k growth strategies best retirement plan catch-up contributions exclusive listings Financial Planning financial planning 2024 Financial Security future planning Indianapolis property market Investing Investment Investment Options Investment Strategies IRA IRA benefits IRA strategies IRA vs 401k Labrosse Real Estate luxury homes luxury real estate maximize retirement savings multi-family investment Indianapolis passive income through real estate Personal Finance premium properties property syndication real estate investment real estate syndication Indianapolis Retirement retirement advice retirement investment Retirement Planning retirement planning 2024 Retirement Savings retirement savings tips retirement strategies retirement tips Savings secure retirement secure retirement funds Wealth Management

Footer

  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms of Use
  • Google News

Recent

  • Roth IRA Contribution and Income Limits for 2025
  • Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s
  • IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024
  • Real Estate Syndication in Indianapolis: Unlocking Investment Potential
  • Maximizing Your 401k at 55 | Retirement Strategies for Growth